Poorly differentiated rhabdomyosarcomas are traditionally distinguished from lymphomas by their absence of lymphoid markers such as immunoglobulin or CD20 expression. We have encountered three alveolar rhahdomyosarcomas that were initially diagnosed as lymphoid neoplasms because of the expression of a lymphocytic phenotype in morphologically undifferentiated tumor cells. Subsequent cytogenetic analysis revealed a t(2;13) in two cases. All cases returred in the chest wall and showed positivity for muscle markers, such as muscle-specific actin, myoglobin, MyoD1, and/or desmin on subsequent immunohistochemistry. The findings in these three cases lead us to conclude that the presence of a lymphoid phenotype does not absolutely exclude the diagnosis of rhabdomyosarcoma.

Pinto, A., Tallini, G., Novak, R.w., Bowen, T., Parham, D.m. (1997). Undifferentiated rhabdomyosarcoma with lymphoid phenotype expression. MEDICAL AND PEDIATRIC ONCOLOGY, 28(3), 165-170 [10.1002/(SICI)1096-911X(199703)28:3<165::AID-MPO1>3.0.CO;2-H].

Undifferentiated rhabdomyosarcoma with lymphoid phenotype expression

Tallini G;
1997

Abstract

Poorly differentiated rhabdomyosarcomas are traditionally distinguished from lymphomas by their absence of lymphoid markers such as immunoglobulin or CD20 expression. We have encountered three alveolar rhahdomyosarcomas that were initially diagnosed as lymphoid neoplasms because of the expression of a lymphocytic phenotype in morphologically undifferentiated tumor cells. Subsequent cytogenetic analysis revealed a t(2;13) in two cases. All cases returred in the chest wall and showed positivity for muscle markers, such as muscle-specific actin, myoglobin, MyoD1, and/or desmin on subsequent immunohistochemistry. The findings in these three cases lead us to conclude that the presence of a lymphoid phenotype does not absolutely exclude the diagnosis of rhabdomyosarcoma.
1997
Pinto, A., Tallini, G., Novak, R.w., Bowen, T., Parham, D.m. (1997). Undifferentiated rhabdomyosarcoma with lymphoid phenotype expression. MEDICAL AND PEDIATRIC ONCOLOGY, 28(3), 165-170 [10.1002/(SICI)1096-911X(199703)28:3<165::AID-MPO1>3.0.CO;2-H].
Pinto, A; Tallini, G; Novak, Rw; Bowen, T; Parham, Dm
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/1050735
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 14
  • OpenAlex ND
social impact